Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of romidepsin and lenalidomide
when combined with rituximab and to see how well this combination works in treating patients
with B-cell non-Hodgkin lymphoma that has returned (recurrent) or did not respond to
treatment (refractory). Monoclonal antibodies, such as rituximab, may block cancer growth in
different ways by targeting certain cells. Romidepsin and lenalidomide may stop the growth of
cancer cells by blocking enzymes needed for cell growth. Giving rituximab together with
romidepsin and lenalidomide may be a better treatment for B-cell non-Hodgkin lymphoma.